Jeff Yass’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,118,275
| Closed | -$10.1M | – | 14204 |
|
|
2025
Q4 | $10.1M | Buy |
1,118,275
+438,297
| +64% | +$3.28M | ﹤0.01% | 3025 |
|
|
2025
Q3 | $2.11M | Buy |
679,978
+192,998
| +40% | +$511K | ﹤0.01% | 5662 |
|
|
2025
Q2 | $1.04M | Buy |
486,980
+214,223
| +79% | +$346K | ﹤0.01% | 7318 |
|
|
2025
Q1 | $314K | Buy |
272,757
+120,121
| +79% | +$206K | ﹤0.01% | 9979 |
|
|
2024
Q4 | $334K | Buy |
152,636
+86,899
| +132% | +$197K | ﹤0.01% | 9587 |
|
|
2024
Q3 | $143K | Buy |
65,737
+34,302
| +109% | +$78.9K | ﹤0.01% | 10786 |
|
|
2024
Q2 | $72.6K | Sell |
31,435
-86,143
| -73% | -$358K | ﹤0.01% | 11225 |
|
|
2024
Q1 | $647K | Sell |
117,578
-205,762
| -64% | -$941K | ﹤0.01% | 7892 |
|
|
2023
Q4 | $799K | Buy |
+323,340
| New | +$3.07M | ﹤0.01% | 7550 |
|
|
2023
Q3 | – | Sell |
-13,219
| Closed | -$457K | – | 13096 |
|
|
2023
Q2 | $434K | Buy |
13,219
+2,788
| +27% | +$96.1K | ﹤0.01% | 8644 |
|
|
2023
Q1 | $349K | Buy |
+10,431
| New | +$406K | ﹤0.01% | 9384 |
|
|
2022
Q4 | – | Sell |
-19,114
| Closed | -$667K | – | 13800 |
|
|
2022
Q3 | $667K | Buy |
+19,114
| New | +$423K | ﹤0.01% | 7699 |
|
Other funds holding VTYX
Jeff Yass's VTYX Position: Q1 2026 in Review
Jeff Yass sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 1,118,275 shares — an estimated $10.1M sold.
Jeff Yass first reported a position in VTYX in Q3 2022 and held it in 12 quarters. The position peaked at $10.1M in Q4 2025. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Jeff Yass reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Jeff Yass sold 1,118,275 Ventyx Biosciences shares in Q1 2026, an estimated $10.1M.
- Jeff Yass first reported a position in Ventyx Biosciences in Q3 2022 and held it in 12 quarters.
- Jeff Yass's Ventyx Biosciences position peaked at $10.1M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.